Multisystem Inflammatory Syndrome in Children - Recognition and Initial Therapy

Key Points

• MIS-C usually develops weeks after SARS-CoV-2 infection rather than during the initial viral illness.
• Shock and myocardial dysfunction can develop rapidly, so cardiac biomarkers and echocardiography are important early tests.
• Bacterial sepsis and toxic shock must be considered and often treated empirically until excluded.
• IVIG plus glucocorticoids is standard first-tier immunomodulation for significant hospitalized MIS-C.
• Repeated large fluid boluses can be harmful when myocardial function is impaired.
• Aspirin and anticoagulation are individualized according to coronary, ventricular, and thrombosis risk.
• All hospitalized MIS-C patients need planned cardiac follow-up after discharge.

Algorithm

1. Recognize persistent fever with multisystem involvement and obtain inflammatory, infectious, and cardiac evaluation.
2. Assess perfusion, oxygenation, ECG, troponin, BNP or NT-proBNP, and echocardiography early.
3. Treat shock with cautious fluid, vasoactive support, and empiric antibiotics while serious bacterial infection remains possible.
4. Consult pediatric cardiology, rheumatology, infectious disease, and critical care for moderate or severe disease.
5. Begin IVIG plus glucocorticoid immunomodulation when MIS-C is established or highly likely.
6. Escalate refractory inflammation with higher-intensity glucocorticoid or a biologic such as anakinra under specialist guidance.
7. Choose aspirin and prophylactic or therapeutic anticoagulation based on bleeding and thrombosis risk.
8. Trend cardiac and inflammatory markers and arrange follow-up echocardiography after discharge.

Clinical Synopsis & Reasoning

Multisystem inflammatory syndrome in children usually appears about 2 to 6 weeks after SARS-CoV-2 infection, which may have been mild, asymptomatic, or unrecognized. The syndrome is now much less common than during the early pandemic but remains clinically important because a previously healthy child can develop rapid cardiovascular collapse. Persistent fever with prominent gastrointestinal symptoms, rash, conjunctival injection, mucosal changes, headache, lethargy, hypotension, or shock should raise suspicion when inflammatory markers are elevated and another diagnosis does not better explain the illness.

Cardiovascular assessment is central. MIS-C can cause myocarditis-like ventricular dysfunction, vasodilatory shock, pericardial effusion, arrhythmias, and coronary artery dilation or aneurysm. Obtain ECG, troponin, BNP or NT-proBNP, and echocardiography when the syndrome is suspected. Some children have normal systolic function initially and deteriorate later, so serial assessment is important when inflammation is substantial. Respiratory symptoms may reflect acute SARS-CoV-2, bacterial pneumonia, pulmonary edema from cardiac dysfunction, or another process.

The differential is deliberately broad because MIS-C is a syndrome of exclusion. Bacterial sepsis, toxic shock syndrome, appendicitis, Kawasaki disease, acute COVID-19, macrophage activation syndrome, systemic juvenile idiopathic arthritis, leukemia, and other infections can overlap. Blood cultures and source-directed testing should be obtained before immunomodulation when feasible, but unstable children require empiric antimicrobial treatment while cultures are pending. CDC surveillance criteria are useful for case classification but should not be used as a rigid bedside threshold that delays treatment of a child with compatible organ dysfunction.

Treatment Strategy & Disposition

Stabilize shock and respiratory failure according to pediatric critical-care principles. Give empiric broad-spectrum antibiotics when bacterial sepsis or toxic shock cannot be excluded, then narrow or stop them as evidence clarifies the diagnosis. Fluid boluses should be cautious and reassessed because myocardial dysfunction is common; early vasoactive support may be preferable to repeated large volumes. Epinephrine or norepinephrine is selected according to the hemodynamic profile and local pediatric critical-care practice.

For immunomodulation, American College of Rheumatology guidance supports IVIG plus low-to-moderate-dose glucocorticoids as first-tier therapy for most hospitalized children with significant MIS-C. IVIG is generally given at 2 g/kg based on ideal body weight with cardiac function and volume status considered. Methylprednisolone or equivalent glucocorticoid is added, with higher-dose pulse therapy reserved for selected refractory or life-threatening disease. Anakinra is a common steroid-sparing or escalation option for refractory disease, macrophage-activation features, or contraindications to other therapy. Treatment should be coordinated with pediatric rheumatology, infectious disease, hematology, and cardiology.

Low-dose aspirin is commonly used in children without bleeding risk, particularly when Kawasaki-like features or coronary changes are present. Therapeutic anticoagulation is indicated for selected patients with large coronary aneurysms, documented thrombosis, or severe ventricular dysfunction, while prophylactic anticoagulation is individualized according to age, immobility, D-dimer, central venous access, obesity, and other thrombosis risks. Follow CBC, inflammatory markers, cardiac biomarkers, ECG, and echocardiography through recovery. Discharge requires stable cardiac function and hemodynamics, a clear steroid taper when applicable, antithrombotic instructions, and cardiology follow-up because cardiac abnormalities can evolve after the acute fever resolves.

Epidemiology / Risk Factors

• MIS-C became substantially less frequent after the early pandemic years but sporadic cases continue.
• It most often affects school-age children but can occur across pediatric age groups.
• Many affected children were previously healthy.
• Severe cases can require ICU care for shock, arrhythmia, or cardiac dysfunction.

Investigations

Common Features

Pharmacology

Prognosis / Complications

• Most children recover with prompt supportive and immunomodulatory therapy.
• Ventricular dysfunction usually improves, but coronary abnormalities and persistent exercise intolerance require follow-up.
• Refractory shock, macrophage activation, thrombosis, and severe neurologic involvement increase risk.
• Long-term outcome data continue to evolve because the syndrome is relatively new.

Patient Education / Counseling

• Explain that MIS-C is an inflammatory complication after infection, not simply persistent contagious COVID-19.
• Review every discharge medication, especially aspirin, anticoagulant, and steroid taper instructions.
• Restrict vigorous activity until cardiology clears the child when myocardial or coronary involvement occurred.
• Seek urgent care for recurrent fever, chest pain, fainting, severe dyspnea, new confusion, or bleeding while on antithrombotic therapy.
• Discuss vaccination and routine preventive care at follow-up after the acute inflammatory period.

Notes

MIS-C now occurs less often, which creates a new diagnostic challenge: clinicians may be less familiar with it precisely when rapid recognition still matters. The syndrome should remain in the differential for a child with fever, inflammation, gastrointestinal symptoms, and unexplained cardiovascular dysfunction after recent SARS-CoV-2 exposure, but declining incidence makes careful exclusion of more common bacterial and surgical diagnoses even more important.

Cardiac follow-up is not optional simply because the child looks well at discharge. Ventricular function, coronary dimensions, rhythm, and exercise tolerance determine the recovery plan. Medication instructions also require precision because aspirin, anticoagulation, and glucocorticoid tapering carry different risks and stop dates.

References

1. CDC: Clinical Overview of Multisystem Inflammatory Syndrome in Children — Link
2. CDC: Clinical Care and Treatment for MIS-C — Link